These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 36028610)

  • 1. Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies.
    Chiriboga CA
    Paediatr Drugs; 2022 Nov; 24(6):585-602. PubMed ID: 36028610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
    Aslesh T; Yokota T
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risdiplam for the treatment of spinal muscular atrophy].
    Vlodavets DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.
    Hjartarson HT; Nathorst-Böös K; Sejersen T
    Drug Des Devel Ther; 2022; 16():1865-1883. PubMed ID: 35734367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Spinal Muscular Atrophy].
    Ishiyama A
    Brain Nerve; 2023 May; 75(5):507-510. PubMed ID: 37194521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advance in Disease Modifying Therapies for Spinal Muscular Atrophy.
    Tsai LK; Ting CH; Liu YT; Hsiao CT; Weng WC;
    Acta Neurol Taiwan; 2024 Sep; 33(3)():81-88. PubMed ID: 39363429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges.
    Haque US; Yokota T
    Genes (Basel); 2024 Jul; 15(8):. PubMed ID: 39202360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
    Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
    Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy.
    Iftikhar M; Frey J; Shohan MJ; Malek S; Mousa SA
    Pharmacol Ther; 2021 Apr; 220():107719. PubMed ID: 33130193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
    Li Y; Zeng H; Wei Y; Ma X; He Z
    Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
    Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O
    Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances and limitations for the treatment of spinal muscular atrophy.
    Day JW; Howell K; Place A; Long K; Rossello J; Kertesz N; Nomikos G
    BMC Pediatr; 2022 Nov; 22(1):632. PubMed ID: 36329412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMN Blood Levels in a Porcine Model of Spinal Muscular Atrophy.
    Iyer CC; Wang X; Renusch SR; Duque SI; Wehr AM; Mo XM; McGovern VL; Arnold WD; Burghes AH; Kolb SJ
    J Neuromuscul Dis; 2017; 4(1):59-66. PubMed ID: 28269795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy.
    Blair HA
    CNS Drugs; 2022 Sep; 36(9):995-1005. PubMed ID: 35960489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.
    Le TT; Pham LT; Butchbach ME; Zhang HL; Monani UR; Coovert DD; Gavrilina TO; Xing L; Bassell GJ; Burghes AH
    Hum Mol Genet; 2005 Mar; 14(6):845-57. PubMed ID: 15703193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy.
    Reilly A; Yaworski R; Beauvais A; Schneider BL; Kothary R
    Hum Mol Genet; 2024 Feb; 33(6):510-519. PubMed ID: 38073249
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.